Pfizer Celebrex Continued Marketing Supported By FDA Cmte.
This article was originally published in The Pink Sheet Daily
Executive Summary
Committee finds celecoxib has cardiovascular side effects but may be safer than some other COX-2 inhibitors. Cardiovascular events may occur only at higher doses used for non-arthritis patients, some committee members suggest.
You may also be interested in...
Celebrex, NSAID Labeling Must Be Updated Within Three Months, FDA Says
FDA's labeling template calls for Pfizer's Celebrex and other prescription NSAIDs to add "black box" warnings on cardiovascular and gastrointestinal risks. FDA is also requiring a warning on skin reactions. The agency issues a medication guide for all NSAIDs.
Celebrex, NSAID Labeling Must Be Updated Within Three Months, FDA Says
FDA's labeling template calls for Pfizer's Celebrex and other prescription NSAIDs to add "black box" warnings on cardiovascular and gastrointestinal risks. FDA is also requiring a warning on skin reactions. The agency issues a medication guide for all NSAIDs.
Celebrex Long-Term Safety Study Planned
Pfizer will work with FDA to design a long-term safety study for Celebrex following the agency's decision to recommend a "black box" warning on the COX-2 inhibitor's increased risk for cardiovascular events